The 25 predicted candidates targeted to the PD-L1/IDO1 dual-target system
| Chemicals | Original functions |
|---|---|
| Androstenol | A postulated pheromone in male |
| Tipifamib | Farnesyl transferase inhibitor |
| Verapamil | Calcium channel blocker |
| IB-MECA | Selective A3 adenosine receptor (A3AR) agonist |
| WH-4023 | Selective dual LCK/SRC inhibitor |
| Atorvastatin | HMG CoA reductase inhibitors, Statin-class |
| PD-0325901 | Selective and non-ATP-competitive MEK inhibitor |
| EMD-386088 | 5-HT6 receptor agonist |
| TWS-119 | GSK-3β inhibitor |
| Fostamatinib | Spleen tyrosine kinase (SYK) inhibitor |
| CC-930 | JNK inhibitor |
| Lapatinib | EGFR, ERBB2 inhibitor |
| SB-216763 | GSK-3 inhibitor |
| RITA | p53-HDM-2 interaction inhibitor |
| PD-0325901 | MEK inhibitor |
| PKC beta-inhibitor | Blocking PKC beta |
| RHO-kinase-inhibitor-iii | Rho-kinase inhibitor and vasodilator |
| Triacsin-c | Production of Streptomyces aureofaciens, ACSL inhibitor |
| TTNPB | RAR agonist |
| AS-703026 | MEK1/2 inhibitor |
| Eicosatetranoic-acid | Cyclooxygenase and lipoxygenases inhibitor |
| PD-98059 | MEK inhibitor |
| Dexamethasone | Glucocorticoid |
| PP-1 | SRC inhibitor |
| AC-55649 | RARβ2 receptor agonist |